Axsome Therapeutics Announces Interim Analysis of STRIDE-1 Trial

Shares of Axsome increased nearly 20 percent after the announcement, but evened out to an overall 13.21-percent increase to $3.

Axsome Therapeutics Announces Positive Outcome of Interim Analysis of STRIDE-1 Phase 3 Trial of AXS-05

Axsome Therapeutics (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today...

Investing in Alzheimer’s Treatments

What is the best way to start investing in Alzheimer's treatments? The space has proven difficult for companies to break...

5 Alzheimer’s Disease Treatment Stocks

Alzheimer's and other forms of dementia cost the US health care system over $259 billion in 2017, and may increase...

Axsome Therapeutics Announces Transition of Chief Medical Officer

NEW YORK, Sept. 02, 2016 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for...